An observational study in Burns, sponsored by Efferon JSC. Withdrawn at 1 site in Russia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Efferon JSC · Observational
No patients meeting the study eligibility criteria were identified
This observational pilot study aims to establish criteria for evaluating the effectiveness of hemoadsorption with the Efferon LPS device in adult patients with burn injury. Participants will be prospectively enrolled into the treatment group and compared with a retrospectively selected control group. Each patient in the treatment group will undergo two hemoadsorption sessions, each lasting 6-12 hours, with a 24 hours interval between sessions. The procedures may be performed in combination with hemofiltration or hemodiafiltration at the investigator's discretion.
Extensive burns represent a severe form of trauma that, according to the World Health Organization, cause more than 180,000 deaths worldwide each year. Despite advances in modern medicine, sepsis and other infectious complications remain leading contributors to mortality among severely burned patients.
The Efferon LPS device, originally developed for sepsis, targets both primary and secondary inflammatory mediators. This technology also shows promise in burn injury, which involves a complex systemic inflammatory response. Burn trauma induces the release of cytokines and damage-associated molecular patterns (DAMPs), while increased intestinal permeability and endotoxin translocation may lead to the appearance of pathogen-associated molecular patterns (PAMPs). Addressing both DAMPs and PAMPs is therefore essential for effective burn injury management. The aim of this study is to identify criteria for evaluating the effectiveness of hemoadsorption with the Efferon LPS device in adult patients with burn injury.
905 studies on the registry are indexed under Burns; 164 are open to participants now.
Browse Burns studies →Efferon JSC is the lead sponsor of 20 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients with thermal burns undergoing treatment in State Novosibirsk Regional Clinical Hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The retrospective control group will include patients from the same medical institution's records from the previous 3 years, matched to the study cohort using propensity score matching. These patients received standard therapy for thermal burns, which could include hemofiltration or hemodiafiltration procedures.
Patients will receive standard therapy for thermal burns treatments and Efferon LPS hemoadsorption procedure. Prospective enrollment.
Device: Efferon LPS
Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity. Two hemoadsorption procedures will be performed per patient, with a duration of 6-12 hours each and an interval of 24 hours between procedures. The procedures may be administered in combination with hemofiltration or hemodiafiltration, as determined by the investigator.
Effect of the Efferon LPS hemoadsorption on ICU length of stay
Time (days) from the start of hemoadsorption to transfer from the ICU
Time frame: 1-28 days
Effect of the Efferon LPS hemoadsorption on need for vasopressor support
Need for vasopressors according to the VIS 2020 scale (Vasoactive-Inotropic Score), a weighted sum of vasoactive and inotropic medication doses; higher scores indicate greater hemodynamic support requirement (worse outcome).
Time frame: 1-28 days
Effect of the Efferon LPS hemoadsorption on pulmonary oxygen metabolic function
Value of oxygenation index (PaO₂/FiO₂ (Pa)) Oxygenation index (PaO₂/FiO₂) = arterial oxygen partial pressure (Pa02, mmHg) / the fraction of inspired oxygen (FiO2).
Time frame: 1-28 days
Effect of the Efferon LPS hemoadsorption on duration of renal replacement therapy (RRT)
Duration of renal replacement therapy (RRT) in hours
Time frame: 1-28 days
Effect of the Efferon LPS hemoadsorption on incidence of septic complications
Frequency of septic complications
Time frame: 1-28 days
Effect of the Efferon LPS hemoadsorption on frequency of surgical interventions
Frequency of surgical interventions
Time frame: 1-28 days
Effect of the Efferon LPS hemoadsoption on 28-day mortality
Mortality rate
Time frame: 1-28 days
Effect of the Efferon LPS hemoadsoption on length of hospital stay
Length of hospital stay
Time frame: 1-60 days
No patients meeting the study eligibility criteria were identified
No patients meeting the study eligibility criteria were identified
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Efferon JSC